The ThinPrep® Pap Test, is the only replacement to the conventional Pap smear that has Food & Drug Administration (FDA) labeling claims stating that the product is significantly more effective than the conventional Pap smear for the detection of low-grade squamous intraepithelial (LSIL) and more severe lesions in a variety of patient populations. Additionally, data from a multi-site clinical outcome trial, in which ThinPrep specimens were collected prospectively and compared against an historical control cohort, indicated a 59.7 percent increase in the detection of high-grade squamous intraepithelial (HSIL) and more severe lesions. More recently the FDA has approved labeling that references multiple peer-reviewed publications which report improved ability of the ThinPrep System to detect glandular disease versus the conventional Pap smear. The clinical information, including a thorough overview and clinical trial details, is available in this section.